文献速递抗栓抗凝管理药物不良反应与药物警戒

达比加群或利伐沙班与维生素K拮抗剂在房颤患者中的治疗持续性比较:法国国家医疗数据库的竞争风险分析

Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
PubMed 文献 · Pharmacotherapy · 2017-12-11

基于法国国家医疗数据库的队列研究,比较非瓣膜性房颤患者起始达比加群、利伐沙班或VKA的1年非持续性率。调整后达比加群(36.8% vs 30.2%)和利伐沙班(33.4% vs 30.4%)的非持续性率均高于VKA。亚组分析中<75岁患者及达比加群150mg起始者差异不显著。

要点

  • 达比加群和利伐沙班的1年非持续性率均高于VKA。
  • 亚组中<75岁患者及达比加群150mg起始者与VKA差异不显著。
  • 因出血住院不能解释高非持续性率。

核心结论

  • 达比加群和利伐沙班的治疗持续性并不优于VKA。
  • 所有口服抗凝药的非持续性率均较高。

研究设计与样本

  • 纳入非瓣膜性房颤起始达比加群(N=11,141)、利伐沙班(N=11,126)或VKA(N=11,998)的患者。
  • 采用逆概率治疗加权调整基线特征,并将死亡作为竞争风险。

主要发现

  • 调整后1年非持续性率:达比加群36.8% vs VKA 30.2%,差异6.6%(95%CI 5.5-7.6)。
  • 调整后1年非持续性率:利伐沙班33.4% vs VKA 30.4%,差异3.0%(95%CI 1.9-4.1)。
  • 亚组分析中<75岁患者:达比加群vs VKA差异0.3%(95%CI -1.4至1.8),利伐沙班vs VKA差异-2.6%(95%CI -4.3至-0.9)。
  • 达比加群150mg起始者vs VKA差异-1.1%(95%CI -3.1至0.7)。

关键数值与推荐

  • 治疗中断定义为换用其他口服抗凝药类别或60天无药物覆盖的间隙。
  • VKA患者还需满足间隙期间无INR监测报销。

临床怎么用

  • 临床选择口服抗凝药时,不应假定DOAC的持续性优于VKA。
  • 对<75岁患者或达比加群150mg起始者,DOAC与VKA的持续性差异可能不明显。

局限性

  • 非持续性率定义基于数据库报销记录,可能受配药和监测行为影响。
  • 观察性研究设计存在残余混杂可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct oral anticoagulants (DOACs) have been proposed as a more convenient alternative to vitamin K antagonists (VKAs), which are commonly associated with poor treatment persistence in non-valvular atrial fibrillation (nv-AF). METHODS: Using data from the French national health care databases (Régime Général, 50 million beneficiaries), a cohort study was conducted to compare the 1-year non-persistence rates in nv-AF patients initiating dabigatran (N=11,141) or rivaroxaban (N=11,126) versus VKA (N=11,998). Treatment discontinuation was defined as a switch between oral anticoagulant (OAC) classes or a 60-day gap with no medication coverage, with the additional criterion of no reimbursement for international normalized ratio monitoring during this gap for VKA patients. Considering death as a competing risk, differences between 1-year discontinuation rates were used to compare each DOAC versus VKA. The 95% confidence intervals (CIs) were estimated via bootstrapping. Baseline patient characteristics were adjusted using inverse probability of treatment weighting. Subgroup analyses considered DOAC dose at initiation, age, risk of stroke, and bleeding. RESULTS: Adjusted 1-year discontinuation rates were higher for dabigatran than for VKA new users (36.8% vs 30.2%; difference: 6.6% [95% CI, 5.5-7.6]) and for rivaroxaban versus VKA new users (33.4% vs 30.4%; 3.0% [1.9-4.1]). Similar differences were found in all subgroup analyses, except in dabigatran and rivaroxaban patients <75 years (dabigatran vs VKA: 0.3% [-1.4 to 1.8]; rivaroxaban vs VKA: -2.6% [-4.3 to -0.9]) and dabigatran 150 mg new users (-1.1% [-3.1 to 0.7]). Consistent results were obtained when considering both switches between OAC classes and death as competing risks of treatment discontinuation. CONCLUSION: Results from this nationwide cohort study showed high non-persistence levels with all OACs and suggest that persistence with both dabigatran and rivaroxaban therapy is not better than persistence with VKA therapy. Hospitalizations for bleeding among non-persistent patients were unlikely to explain these high non-persistence rates.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Maura G, Billionnet C, Alla F, et al. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. Pharmacotherapy. 2017. PMID: 29028119. doi:10.1002/phar.2046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。